Rhythm Pharmaceuticals, Inc. RYTM Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s retained earnings?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported retained earnings of -$1.41B in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s retained earnings decreased by 16.8% year-over-year, from -$1.2B to -$1.41B.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s retained earnings has grown at a 24.1% compound annual growth rate (CAGR), from -$459.33M to -$1.35B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.